AI Article Synopsis

  • CD4T cells responsible for transferring transplant tolerance are short-lived without specific stimulation, but their survival can be enhanced by cytokines like IFN-γ.
  • In a study involving DA rats and PVG heart transplants, CD4T cells maintained their tolerance-transfer ability when cultured with IFN-γ and specific-donor alloantigens, preventing graft rejection.
  • The presence of IFN-γ in culture inhibited the proliferation of tolerant CD4T cells while sustaining their expression of IFN-γ receptors, indicating it plays a crucial role in maintaining their tolerance function.

Article Abstract

CD4T cells that transfer alloantigen-specific transplant tolerance are short lived in culture unless stimulated with specific-donor alloantigen and lymphocyte derived cytokines. Here, we examined if IFN-γ maintained survival of tolerance transferring CD4T cells. Alloantigen-specific transplant tolerance was induced in DA rats with heterotopic adult PVG heart allografts by a short course of immunosuppression and these grafts functioned for >100days with no further immunosuppression. In previous studies, we found the CD4T cells from tolerant rats that transfer tolerance to an irradiated DA host grafted with a PVG heart, lose their tolerance transferring ability after 3days of culture, either with or without donor alloantigen, and effect rejection of specific-donor grafts. If cultures with specific-donor alloantigen are supplemented by supernatant from ConA activated lymphocytes the tolerance transferring cells survive, suggesting these cells depend on cytokines for their survival. In this study, we found addition of rIFN-γ to MLC with specific-donor alloantigen maintained the capacity of tolerant CD4T cells to transfer alloantigen-specific tolerance and their ability to suppress PVG allograft rejection mediated by co-administered naïve CD4T cells. IFN-γ suppressed the in vitro proliferation of tolerant CD4T cells. Tolerant CD4CD25T cells did not proliferate in MLC to PVG stimulator cells with no cytokine added, but did when IFN-γ was present. IFN-γ did not alter proliferation of tolerant CD4CD25T cells to third-party Lewis. Tolerant CD4CD25T cells' expression of IFN-γ receptor (IFNGR) was maintained in culture when IFN-γ was present. This study suggested that IFN-γ maintained tolerance mediating alloantigen-specific CD4CD25T cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trim.2017.05.002DOI Listing

Publication Analysis

Top Keywords

cd4t cells
24
cells
14
transplant tolerance
12
specific-donor alloantigen
12
tolerance transferring
12
tolerant cd4cd25t
12
cd4cd25t cells
12
tolerance
9
cd4t regulatory
8
regulatory cells
8

Similar Publications

In Vitro Evaluation of Bunyavirus T Cell Immunity.

Methods Mol Biol

December 2024

Pediatric Infectious Disease and Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Characterization and quantitation of T cell responses following infection and/or vaccination can provide insight into mechanisms of host cell immunity that provide resolution of acute infection or protection from future infection or disease. While these types of studies are very advanced for viruses such as HIV, influenza, and SARS-CoV-2, they are less well developed for most of the Bunyaviruses. Cytotoxic CD8T cells are especially relevant in the context of viral infections since they recognize virus-infected cells via interaction of the T cell receptor with virally derived peptides presented in the context of MHCI.

View Article and Find Full Text PDF

Introduction: Cutaneous immune-mediated adverse drug reactions are more prevalent in people with human immunodeficiency virus (PWH). Severe cutaneous adverse drug reactions (SCAR) are a life-threatening subset of cutaneous adverse drug reactions (CADRs) and a significant public health issue in settings endemic for human immunodeficiency virus and tuberculosis. However, limited data are available on CADR requiring hospitalisation in African settings.

View Article and Find Full Text PDF
Article Synopsis
  • This study explores blood biomarkers that can predict responses to immune checkpoint inhibitors (ICIs) for patients with recurrent/metastatic head and neck squamous cell carcinoma, addressing challenges like tumor sample variability.
  • Researchers enrolled 100 patients and analyzed blood immune profiles, focusing on factors like tumor mutational burden (TMB) and PD-L1 scores, with a goal to find associations with treatment outcomes.
  • Key findings revealed that high levels of neutrophils and monocytes were linked to worse survival, while higher CD4T cells correlated with better outcomes, highlighting the potential of using blood tests for predicting ICI treatment responses.
View Article and Find Full Text PDF

High-dimensional profiling of immune responses to kidney transplant reveals heterogeneous T helper 1 and B cell effectors associated with rejection.

Am J Transplant

October 2024

Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address:

Article Synopsis
  • Rejection is a major cause of kidney transplant failure, and this study explores the immune cell types involved in different rejection types at a detailed level.
  • Researchers analyzed blood samples from 76 kidney transplant patients, using advanced techniques to identify specific CD4 T and B cell characteristics that differentiate stable transplants from those experiencing rejection.
  • Results revealed distinct immune cell profiles for T cell-mediated versus antibody-mediated rejection, enhancing our understanding of how rejection occurs and paving the way for targeted treatments.
View Article and Find Full Text PDF

Isotretinoin promotes elimination of translation-competent HIV latent reservoirs in CD4T cells.

PLoS Pathog

October 2024

Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington DC, United States of America.

Development of novel therapeutic strategies that reactivate latent HIV and sensitize reactivated cells to apoptosis is crucial towards elimination of the latent viral reservoir. Among the clinically relevant latency reversing agents (LRA) under investigation, the γc-cytokine IL-15 and the superagonist N-803 have been shown to reactivate latent HIV ex vivo and in vivo. However, their clinical benefit can be hindered by IL-15 promoting survival of infected cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!